Norway Cancer Diagnostics Market Size & Outlook, 2023-2030
Norway cancer diagnostics market, 2018-2030 (US$M)
Related Markets
Norway cancer diagnostics market highlights
- The Norway cancer diagnostics market generated a revenue of USD 1,185.6 million in 2023 and is expected to reach USD 1,692.8 million by 2030.
- The Norway market is expected to grow at a CAGR of 5.2% from 2024 to 2030.
- In terms of segment, consumables was the largest revenue generating product in 2023.
- Consumables is the most lucrative product segment registering the fastest growth during the forecast period.
Cancer diagnostics market data book summary
| Market revenue in 2023 | USD 1,185.6 million |
| Market revenue in 2030 | USD 1,692.8 million |
| Growth rate | 5.2% (CAGR from 2023 to 2030) |
| Largest segment | Consumables |
| Fastest growing segment | Consumables |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Services, Instruments, Consumables |
| Key market players worldwide | Abbott Laboratories, Roche Holding AG, GE HealthCare Technologies Inc Common Stock, Qiagen NV, Becton Dickinson & Co, Koninklijke Philips NV, Siemens Healthineers AG ADR, Hologic Inc, Thermo Fisher Scientific Inc, Illumina Inc |
Other key industry trends
- In terms of revenue, Norway accounted for 1.1% of the global cancer diagnostics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany cancer diagnostics market is projected to lead the regional market in terms of revenue in 2030.
- Germany is the fastest growing regional market in Europe and is projected to reach USD 9,637.9 million by 2030.
Consumables was the largest segment with a revenue share of 59.93% in 2023. Horizon Databook has segmented the Norway cancer diagnostics market based on services, instruments, consumables covering the revenue growth of each sub-segment from 2018 to 2030.
In December 2021, Illumina, Inc. announced that it would support Norway’s precision medicine study to evaluate blood-based Comprehensive Genomic Profiling (CGP) efficiency in selecting cancer therapy. The study would also evaluate the cost-effectiveness of blood-based CGP implementation in the healthcare system.
Tissue sampling could be replaced with less invasive CGP testing on blood samples, thus expanding the number of people whose tumors can be profiled and who can be enrolled in clinical trials for cancer therapy selection.
As sequencing is used more frequently in clinical settings in Norway, practical and ethical concerns are emerging around creating Informed Consent (IC) documents and their processes. It is difficult to bridge the gap between Norwegian legislation & regulations and clinical practice to build a suitable IC process for testing in the clinical setting.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Diagnostics Market Scope
Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Norway cancer diagnostics market size, by product, 2018-2030 (US$M)
Norway Cancer Diagnostics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
